Biotech veteran Michael Gilman joins Arrakis full-time after $75M round

Biogen veteran Michael Gilman, a well-known figure in the Boston-area biotech industry, is joining Waltham biotech Arrakis Therapeutics full-time after the startup raised a further $75 million. Arrakis Therapeutics closed a $75 million Series B round Thursday with financing from new investors GV, Alexandria Venture Investments and Chinese investment firm WuXi AppTec Venture Fund, according to a press release. Following the financing round, Gilman will leave the other startup with which he's been…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news